Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates

Core Viewpoint - Integra LifeSciences reported quarterly earnings of $0.97 per share, exceeding the Zacks Consensus Estimate of $0.85 per share, and showing an increase from $0.89 per share a year ago, representing an earnings surprise of 14.12% [1][2] Financial Performance - The company posted revenues of $442.65 million for the quarter ended December 2024, which was 0.45% below the Zacks Consensus Estimate, but an increase from $397.04 million year-over-year [2] - Over the last four quarters, Integra has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Integra shares have declined approximately 2.8% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The current Zacks Rank for Integra is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.54 on revenues of $413.99 million, and for the current fiscal year, it is $2.50 on revenues of $1.71 billion [7] - The estimate revisions trend for Integra is mixed, and changes in these estimates could occur following the recent earnings report [6] Industry Context - The Medical - Instruments industry, to which Integra belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]